Get the Stockscreener App
1.39
6.08%
-0.09
Pre-market:
1.39
Cerus Corp stock is traded at $1.39, with a volume of 1.45M.
It is down -6.08% in the last 24 hours and down -22.78% over the past month.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
See More
Previous Close:
$1.48
Open:
$1.47
24h Volume:
1.45M
Relative Volume:
1.06
Market Cap:
$258.25M
Revenue:
$156.37M
Net Income/Loss:
$-37.49M
P/E Ratio:
-6.619
EPS:
-0.21
Net Cash Flow:
$-47.77M
1W Performance:
-9.15%
1M Performance:
-22.78%
6M Performance:
-32.85%
1Y Performance:
-31.53%
1-Day Range:
$1.39
$1.475
1-Week Range:
$1.39
$1.54
52-Week Range:
$1.375
$2.54
Cerus Corp Stock (CERS) Company Profile
Name
Cerus Corp
Sector
Industry
Phone
(925) 288-6000
Address
1220 CONCORD AVENUE, CONCORD, CA
Compare CERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERS
Cerus Corp
|
1.39 | 258.25M | 156.37M | -37.49M | -47.77M | -0.21 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Cerus Corp Stock (CERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-12-24 | Initiated | Craig Hallum | Buy |
| Jan-20-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-17-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-26-20 | Initiated | BTIG Research | Buy |
| Nov-13-19 | Upgrade | BTIG Research | Neutral → Buy |
| Aug-28-19 | Initiated | Stifel | Buy |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-08-17 | Resumed | BTIG Research | Neutral |
| Jul-07-16 | Resumed | Cantor Fitzgerald | Buy |
| Dec-17-15 | Downgrade | Wedbush | Outperform → Neutral |
| May-02-14 | Reiterated | MLV & Co | Buy |
| Apr-24-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-15-13 | Reiterated | MLV & Co | Buy |
| Apr-17-12 | Initiated | Cantor Fitzgerald | Buy |
| Feb-29-12 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-10-11 | Reiterated | MLV & Co | Buy |
| Jun-03-11 | Initiated | Wedbush | Outperform |
| Mar-04-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-09-10 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-26-09 | Upgrade | Avondale | Mkt Perform → Mkt Outperform |
View All
Cerus Corp Stock (CERS) Latest News
Closing Bell Recap: Cerus Corp (CERS) Ends at 1.48, Reflecting a -0.67 Downturn - The Dwinnex
Cerus Stock: Insider Sales Amid Positive Business Growth - sharewise
Cerus Corp chief medical officer sells $39,156 in stock By Investing.com - Investing.com Canada
Cerus Corp chief legal officer sells $41,130 in stock By Investing.com - Investing.com South Africa
Cerus Corp COO Vivek Jayaraman sells $50,930 in stock - Investing.com India
Cerus Corp CEO William Greenman sells $91,354 in stock - Investing.com
Cerus corp CFO Kevin Green sells $46,659 in stock - Investing.com
Cerus Corp COO Vivek Jayaraman sells $50,930 in stock By Investing.com - Investing.com UK
Cantor Fitzgerald maintains Cerus stock $4 target, Overweight rating - Investing.com
Cantor Fitzgerald maintains Cerus stock $4 target, Overweight rating By Investing.com - Investing.com UK
Cerus Corp chief legal officer sells $104,885 in stock By Investing.com - Investing.com South Africa
Cerus secures CE mark approval for LED-based illumination device - Yahoo Finance
Cerus corp COO Vivek Jayaraman sells $16,692 in stock By Investing.com - Investing.com South Africa
Cerus corp CEO William Greenman sells shares worth $35,651 By Investing.com - Investing.com South Africa
Cerus Stock: Execs Sell Shares Amid Strong Financials - sharewise
Cerus CFO Kevin Green sells $108,658 in company stock By Investing.com - Investing.com South Africa
Cerus Corp chief medical officer sells $90,570 in stock By Investing.com - Investing.com South Africa
Cerus Corp chief medical officer sells $90,570 in stock - Investing.com India
Cerus corp COO Vivek Jayaraman sells $16,692 in stock - Investing.com India
Cerus corp CEO William Greenman sells shares worth $35,651 - Investing.com India
Cerus CFO Kevin Green sells $108,658 in company stock - Investing.com
CERUS CORP Executives Sell Shares - TradingView
Cerus Corp chief legal officer sells $104,885 in stock - Investing.com
Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200) - Yahoo Finance
Cerus Corp (NASDAQ: CERS) Stock Forecast: Could Pass $3 In A Year - Stocks Register
ARK Investment Management LLC Has $32.06 Million Stake in Cerus Co. (NASDAQ:CERS) - MarketBeat
Cerus (CERS) Expected to Announce Earnings on Tuesday - MarketBeat
CERUS CORP SEC 10-K Report - TradingView
Cerus (NASDAQ:CERS) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Cerus targets 8%-11% revenue growth for 2025 with strong IFC demand and global expansion - MSN
Cerus Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Canada Finance
Cerus: Q4 Earnings Snapshot - CTPost
Cerus Corp (CERS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow - Yahoo Finance
Cerus Corp (CERS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow By GuruFocus - Investing.com Canada
Earnings call transcript: Cerus Q4 2024 beats EPS forecast, stock dips - Investing.com
Cerus Corp (CERS) Q4 Earnings: Revenue Surpasses Estimates at $5 - GuruFocus.com
Cerus earnings beat by $0.01, revenue topped estimates - Investing.com
Cerus: Q4 Earnings Snapshot -February 20, 2025 at 04:21 pm EST - Marketscreener.com
Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results - Yahoo Finance
What To Expect From Cerus Corp (CERS) Q4 2024 Earnings - GuruFocus.com
Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Decreases Position in Cerus Co. (NASDAQ:CERS) - MarketBeat
The Psychology of Cerus Corp Inc. (CERS) Price Performance: Understanding Market Sentiment - The InvestChronicle
CERS Earnings Alert: Cerus Schedules Critical Year-End Financial ReportKey Details Inside - StockTitan
Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025 - Yahoo Finance
Cerus Corp announces director will not seek re-election By Investing.com - Investing.com Nigeria
Cerus Corp announces director will not seek re-election - Investing.com India
A Look at Cerus Corp (CERS) Shares in the Recent Past Indicates Growth - SETE News
A closer look at Cerus Corp (CERS)’s stock price trends - US Post News
Metric Analysis: Cerus Corp (CERS)’s Key Ratios in the Limelight - The Dwinnex
Cerus (NASDAQ:CERS) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Cerus Corp Stock (CERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cerus Corp Stock (CERS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jayaraman Vivek K | Chief Operating Officer |
Mar 07 '25 |
Sale |
1.50 |
33,999 |
50,931 |
1,507,315 |
| Greenman William Mariner | President and CEO |
Mar 07 '25 |
Sale |
1.50 |
60,984 |
91,354 |
4,309,758 |
| Green Kevin Dennis | Chief Financial Officer |
Mar 07 '25 |
Sale |
1.50 |
31,148 |
46,660 |
935,754 |
| Benjamin Richard J | Chief Medical Officer |
Mar 07 '25 |
Sale |
1.50 |
26,139 |
39,156 |
734,799 |
| Jensen Chrystal | Chief Legal Officer |
Mar 04 '25 |
Sale |
1.58 |
66,292 |
104,885 |
405,198 |
| Jayaraman Vivek K | Chief Operating Officer |
Mar 04 '25 |
Sale |
1.55 |
10,780 |
16,693 |
905,828 |
| Greenman William Mariner | President and CEO |
Mar 04 '25 |
Sale |
1.55 |
23,023 |
35,651 |
3,230,000 |
| Green Kevin Dennis | Chief Financial Officer |
Mar 03 '25 |
Sale |
1.58 |
60,656 |
95,673 |
493,862 |
| Green Kevin Dennis | Chief Financial Officer |
Mar 04 '25 |
Sale |
1.55 |
8,386 |
12,986 |
554,518 |
| Benjamin Richard J | Chief Medical Officer |
Mar 03 '25 |
Sale |
1.58 |
51,254 |
80,828 |
400,665 |
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):